CTx-1301 Presentation at AACAP Annual Meeting
Cingulate Inc. is thrilled to announce a significant milestone for its lead ADHD candidate, CTx-1301, at a renowned annual meeting for child and adolescent mental health. The promising data from CTx-1301 is set to be highlighted during a podium presentation at the upcoming meeting, showcasing the growing interest in innovative ADHD treatments.
About CTx-1301
CTx-1301, which contains dexmethylphenidate HCl, is expertly designed as a once-daily, extended-release formulation, thanks to Cingulate’s advanced Precision Timed Release™ (PTR™) drug-delivery platform. This formulation aims to enhance the treatment adherence of individuals battling ADHD, aiming to alleviate symptoms effectively throughout the entire day.
Significance of the Presentation
The presentation is scheduled to be delivered by Dr. Ann Childress, a distinguished ADHD specialist with an extensive background in psychiatric research. During her lecture entitled “Efficacy and Safety of CTx-1301 in Pediatric Subjects With ADHD,” Dr. Childress will delve into the pivotal Phase 3 trial findings that indicate the effectiveness and safety of CTx-1301.
Insights from Dr. Childress
Dr. Childress expressed enthusiasm about sharing the results, stating, “This pivotal trial's findings offer critical insights into the efficacy of CTx-1301, which could significantly improve the lives of children with ADHD through its convenient once-daily dosing.” Such compelling results not only underline CTx-1301’s potential but also provide healthcare professionals with the reassurance needed when recommending ADHD treatments.
Understanding ADHD
Attention-Deficit/Hyperactivity Disorder (ADHD) affects a staggering number of individuals, with an estimated 20 million diagnosed in the U.S. alone. The disorder is characterized by inattention, hyperactivity, and impulsivity, which can lead to significant challenges in academic, professional, and social settings. Due to the nature of ADHD, stimulant medications are often the first line of treatment, yet many of the current options fall short, requiring multiple daily doses that can lead to inconsistent symptom management.
The Promise of CTx-1301
CTx-1301 is designed not only to take on the limitations of existing stimulant therapies but also to provide a reliable and effective solution. Its unique formulation facilitates a swift onset of effects with sustained release, ensuring that users experience optimal symptom control throughout the day. With its innovative approach, CTx-1301 has garnered significant interest within the ADHD community and beyond.
Cingulate’s Commitment to Patient Care
The dedication of Cingulate Inc. to improving patient outcomes is evident in its efforts to develop next-generation pharmaceutical products utilizing its proprietary PTR™ technology. Besides CTx-1301, Cingulate is also venturing into other neuropsychiatric conditions, reducing burdens associated with daily medication regimens.
Dr. Ann Childress’ Expertise
With over 35 years of experience in psychiatry, Dr. Ann Childress is at the forefront of ADHD research. Her commitment to enhancing treatment options for ADHD is reflected in her extensive experience as a principal investigator for multiple clinical studies, including her current role in Cingulate’s Phase 3 trials. Her contributions are invaluable as they help shape the future landscape of ADHD treatment.
Looking Ahead
As Cingulate Inc. prepares for the AACAP Annual Meeting, the excitement around CTx-1301’s potential to revolutionize ADHD treatment continues to build. The upcoming presentation is not only a chance to share findings but also an opportunity to connect with fellow researchers and clinicians in the field, sparking discussions around improving lives through innovative treatments.
Media and Investor Information
For further inquiries or to learn more about Cingulate’s advancements and offerings, please reach out to the Vice President of Corporate Communications, Thomas Dalton. He can be contacted directly via phone at (913) 942-2301 or through email at tdalton@cingulate.com. Cingulate is laser-focused on pioneering solutions in ADHD and other neuropsychiatric conditions, and staying informed about these developments is essential for all stakeholders.
Frequently Asked Questions
What is CTx-1301?
CTx-1301 is a once-daily ADHD medication developed by Cingulate that aims to provide sustained symptom control throughout the day using the Precision Timed Release technology.
Who is presenting the data on CTx-1301?
Dr. Ann Childress, a prominent ADHD specialist, is presenting the data at the AACAP Annual Meeting.
Why is CTx-1301 significant for ADHD treatment?
CTx-1301 addresses limitations of current ADHD medications, such as inconsistent duration and the need for multiple doses, offering a more effective treatment option.
What does Cingulate Inc. do?
Cingulate Inc. is a biopharmaceutical company focused on developing next-generation pharmaceutical products, especially in ADHD and other neuropsychiatric conditions.
How can I learn more about Cingulate Inc.?
For more information, you can contact Thomas Dalton, Vice President of Corporate Communications, or visit Cingulate's official website.
